Source: Fox News
Summary
The Trump administration has announced that Medicaid will no longer fund child sex-change hormones or surgeries, citing a lack of reliable evidence of clinical benefit and potential serious health risks. The decision, made by the Centers for Medicare & Medicaid Services (CMS), will also affect the Children’s Health Insurance Program (CHIP). Mental health treatments for gender dysmorphia will continue to be covered. The move comes after years of controversy over federal funding of such procedures.
Our Reading
As expected, the matter has reached another stage.
The Trump administration has drawn a line: no more taxpayer-funded sex-rejecting procedures for children. Dr. Mehmet Oz says the decision is “consistent with [the Trump administration’s] commitment to protect children.” The rule will not affect mental health treatments, but will stop funding for cross-sex hormones, puberty blockers, and sex-change surgical operations. The decision is based on research that identified significant evidence gaps and documented serious safety concerns.
The CMS points to the UK’s Cass Review as a cornerstone piece of research informing the decision. The review concluded that research on medical interventions was limited and not definitive.
The decision is a performance of protection, a ritual of responsibility. The administration is drawing a line, setting a boundary, and making a statement. The move is a repetition of a familiar pattern: controversy, debate, and finally, a decision that reinforces the status quo.
And so, the script is followed, the roles are played, and the scene is set for the next act.
Author: Evan Null
